EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

Pre-Launch

empagliflozin, metformin hydrochloride

ANDATABLET, EXTENDED RELEASE

Lifecycle

Pre-Launch

Data completeness

2/8 — Basic

EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (empagliflozin, metformin hydrochloride) by Boehringer Ingelheim is contain: empagliflozin, a sglt2 inhibitor, and metformin hcl, a biguanide. Approved for type 2 diabetes mellitus, heart failure, chronic kidney disease and 2 more indications.

Drug data last refreshed 1mo ago

Mechanism of Action

contain: empagliflozin, a SGLT2 inhibitor, and metformin HCl, a biguanide. Empagliflozin Empagliflozin is an inhibitor of SGLT2, the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, empagliflozin reduces…

Indications (5)

Worked on EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.